Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients

Immunobiology

Volumn 221, Issue 4, 2016, Pages 503-511

  Schmidt, Christoph Q ^a   Harder, Markus J ^a   Nichols, Eva Maria ^b   Hebecker, Mario ^c   Anliker, Markus ^d   Höchsmann, Britta ^d   Simmet, Thomas ^a   Csincsi, Ádám I ^e   Uzonyi, Barbara ^f   Pappworth, Isabel Y ^b   Ricklin, Daniel ^g   Lambris, John D ^g   Schrezenmeier, Hubert ^d   Józsi, Mihály ^e   Marchbank, Kevin J ^b  

^a UNIVERSITY OF ULM   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c HANS KNÖLL INSTITUTE   (Germany)

^d Institute of Transfusion Medicine   (Germany)

^e EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^f MTA ELTE Immunology Research Group Eötvös University   (Hungary)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alternative pathway; Complement targeted inhibition; MiniFH; Paroxysmal nocturnal hemoglobinuria

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 OPSONIN TARGETED INHIBITOR; COMPLEMENT INHIBITOR; ECULIZUMAB; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT FACTOR H; HYBRID PROTEIN; MONOCLONAL ANTIBODY; OPSONIN; TT30 FUSION PROTEIN, HUMAN;

ARTICLE; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG MECHANISM; ERYTHROCYTE; GENOTYPE; HEMOLYSIS; HETEROZYGOSITY; HUMAN; HUMAN CELL; IC50; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BIOSYNTHESIS; CELL CULTURE; COMPLEMENT ALTERNATIVE PATHWAY; DRUG EFFECTS; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEMOGLOBINURIA, PAROXYSMAL; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN ENGINEERING; RABBIT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT FACTOR H; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, ALTERNATIVE; ERYTHROCYTES; ESCHERICHIA COLI; GENE EXPRESSION; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; HUMANS; MOLECULAR TARGETED THERAPY; OPSONIN PROTEINS; PROTEIN ENGINEERING; RABBITS; RECEPTORS, COMPLEMENT 3D; RECOMBINANT FUSION PROTEINS;

EID: 84953774995     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.12.009     Document Type: Article

References (57)

1. Atkinson C., Song H., Lu B., Qiao F., Burns T.A., Holers V.M., Tsokos G.C., Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J. Clin. Invest. 2005, 115:2444-2453. 10.1172/JCI25208.
2. Blaum B.S., Hannan J.P., Herbert A.P., Kavanagh D., Uhrín D., Stehle T. Structural basis for sialic acid-mediated self-recognition by complement Factor H. Nat. Chem. Biol. 2015, 11:77-82. 10.1038/nchembio.1696.
3. Brandstätter H., Schulz P., Polunic I., Kannicht C., Kohla G., Römisch J. Purification and biochemical characterization of functional complement Factor H from human plasma fractions. Vox Sang. 2012, 103:201-212. 10.1111/j. 1423-0410.2012.01610. x.
4. Brodsky R.A., Young N.S., Antonioli E., Risitano A.M., Schrezenmeier H., Schubert J., Gaya A., Coyle L., de Castro C., Fu C.-L., Maciejewski J.P., Bessler M., Kroon H.-A., Rother R.P., Hillmen P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008, 111:1840-1847. 10.1182/blood-2007-06-094136.
5. Charreau B., Cassard A., Tesson L., Le Mauff B., Navenot J.M., Blanchard D., Lublin D., Soulillou J.P., Anegon I. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation 1994, 58:1222-1229.
6. Davies A., Simmons D.L., Hale G., Harrison R.A., Tighe H., Lachmann P.J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 1989, 170:637-654.
7. Davitz M.A., Low M.G., Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J. Exp. Med. 1986, 163:1150-1161.
8. Ezzell J.L., Wilcox L.A., Bernshaw N.J., Parker C.J. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement. Blood 1991, 77:2764-2773.
9. Fakhouri F., de Jorge E.G., Brune F., Azam P., Cook H.T., Pickering M.C. Treatment with human complement Factor H rapidly reverses renal complement deposition in Factor H-deficient mice. Kidney Int. 2010, 78:279-286. 10.1038/ki.2010.132.
10. Ferreira V.P., Herbert A.P., Hocking H.G., Barlow P.N., Pangburn M.K. Critical role of the C-terminal domains of Factor H in regulating complement activation at cell surfaces. J. Immunol. 2006, 177:6308-6316.
11. Ferreira V.P., Pangburn M.K. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood 2007, 110:2190-2192. 10.1182/blood-2007-04-083170.
12. Fridkis-Hareli M., Storek M., Mazsaroff I., Risitano A.M., Lundberg A.S., Horvath C.J., Holers V.M. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011, 118:4705-4713. 10.1182/blood-2011-06-359646.
13. Hakobyan S., Harris C.L., Tortajada A., Goicochea de Jorge E., García-Layana A., Fernández-Robredo P., Rodríguez de Córdoba S., Morgan B.P. Measurement of Factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2008, 49:1983-1990. 10.1167/iovs.07-1523.
14. Hebecker M., Alba-Domínguez M., Roumenina L.T., Reuter S., Hyvärinen S., Dragon-Durey M.-A., Jokiranta T.S., Sánchez-Corral P., Józsi M. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional Factor H. J. Immunol. 2013, 191:912-921. 10.4049/jimmunol.1300269.
15. Herbert A.P., Makou E., Chen Z.A., Kerr H., Richards A., Rappsilber J., Barlow P.N. Complement evasion mediated by enhancement of captured Factor H: implications for protection of self-surfaces from complement. J. Immunol. 2015, 195:4986-4998. 10.4049/jimmunol.1501388.
16. Hill A., Rother R.P., Arnold L., Kelly R., Cullen M.J., Richards S.J., Hillmen P. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010, 95:567-573. 10.3324/haematol.2009.007229.
17. Hillmen P., Hall C., Marsh J.C.W., Elebute M., Bombara M.P., Petro B.E., Cullen M.J., Richards S.J., Rollins S.A., Mojcik C.F., Rother R.P. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 2004, 350:552-559. 10.1056/nejmoa031688.
18. Hillmen P., Young N.S., Schubert J., Brodsky R.A., Socié G., Muus P., Röth A., Szer J., Elebute M.O., Nakamura R., Browne P., Risitano A.M., Hill A., Schrezenmeier H., Fu C.-L., Maciejewski J., Rollins S.A., Mojcik C.F., Röther R.P., Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 2006, 355:1233-1243. 10.1056/nejmoa061648.
19. Höchsmann B., Leichtle R., von Zabern I., Kaiser S., Flegel W.A., Schrezenmeier H. Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test. Vox Sang. 2012, 102:159-166. 10.1111/j.1423-0410.2011.01530.x.
20. Höchsmann B., Rojewski M., Schrezenmeier H. Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. Ann. Hematol. 2011, 90:887-899. 10.1007/s00277-011-1177-4.
21. Holers V.M., Rohrer B., Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv. Exp. Med. Biol. 2013, 735:137-154.
22. Holguin M.H., Fredrick L.R., Bernshaw N.J., Wilcox L.A., Parker C.J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 1989, 84:7-17. 10.1172/jci114172.
23. Holguin M.H., Wilcox L.A., Bernshaw N.J., Rosse W.F., Parker C.J. Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood 1990, 75:284-289.
24. Kelly R.J., Hill A., Arnold L.M., Brooksbank G.L., Richards S.J., Cullen M., Mitchell L.D., Cohen D.R., Gregory W.M., Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011, 117:6786-6792. 10.1182/blood-2011-02-333997.
25. Lachmann P.J. The amplification loop of the complement pathways. Adv. Immunol. 2009, 104:115-149. 10.1016/S0065-2776(08) 04004-2.
26. Lin Z., Schmidt C.Q., Koutsogiannaki S., Ricci P., Risitano A.M., Lambris J.D., Ricklin D. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood 2015, 10.1182/blood-2015-02-625871.
27. Meri S., Pangburn M.K. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on Factor H. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:3982-3986.
28. Morgan H.P., Schmidt C.Q., Guariento M., Blaum B.S., Gillespie D., Herbert A.P., Kavanagh D., Mertens H.D.T., Svergun D.I., Johansson C.M., Uhrín D., Barlow P.N., Hannan J.P. Structural basis for engagement by complement Factor H of C3b on a self surface. Nat. Struct. Mol. Biol. 2011, 18:463-470. 10.1038/nsmb.2018.
29. Nichols E.-M., Barbour T.D., Pappworth I.Y., Wong E.K.S., Palmer J.M., Sheerin N.S., Pickering M.C., Marchbank K.J. An extended mini-complement Factor H molecule ameliorates experimental C3 glomerulopathy. Kidney Int. 2015, 10.1038/ki.2015.233.
30. Nicholson-Weller A., March J.P., Rosenfeld S.I., Austen K.F. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:5066-5070.
31. Nishimura J., Yamamoto M., Hayashi S., Ohyashiki K., Ando K., Brodsky A.L., Noji H., Kitamura K., Eto T., Takahashi T., Masuko M., Matsumoto T., Wano Y., Shichishima T., Shibayama H., Hase M., Li L., Johnson K., Lazarowski A., Tamburini P., Inazawa J., Kinoshita T., Kanakura Y. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med. 2014, 370:632-639. 10.1056/nejmoa1311084.
32. Oppermann M., Manuelian T., Józsi M., Brandt E., Jokiranta T.S., Heinen S., Meri S., Skerka C., Götze O., Zipfel P.F. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin. Exp. Immunol. 2006, 144:342-352. 10.1111/j.1365-2249.2006.03071. x.
33. Pangburn M.K., Schreiber R.D., Müller-Eberhard H.J. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:5430-5434.
34. Parker C.J. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp. Hematol. 2007, 35:523-533. 10.1016/j.exphem.2007.01.046.
35. Peffault de Latour R., Fremeaux-Bacchi V., Porcher R., Xhaard A., Rosain J., Castaneda D.C., Vieira-Martins P., Roncelin S., Rodriguez-Otero P., Plessier A., Sicre de Fontbrune F., Abbes S., Robin M., Socié G. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015, 125:775-783. 10.1182/blood-2014-03-560540.
36. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797. 10.1038/ni.1923.
37. Risitano A.M., Notaro R., Marando L., Serio B., Ranaldi D., Seneca E., Ricci P., Alfinito F., Camera A., Gianfaldoni G., Amendola A., Boschetti C., Di Bona E., Fratellanza G., Barbano F., Rodeghiero F., Zanella A., Iori A.P., Selleri C., Luzzatto L., Rotoli B. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009, 113:4094-4100. 10.1182/blood-2008-11-189944.
38. Risitano A.M., Notaro R., Pascariello C., Sica M., del Vecchio L., Horvath C.J., Fridkis-Hareli M., Selleri C., Lindorfer M.A., Taylor R.P., Luzzatto L., Holers V.M. The complement receptor 2/Factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012, 119:6307-6316. 10.1182/blood-2011-12-398792.
39. Risitano A.M., Perna F., Selleri C. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. Mini Rev. Med. Chem. 2011, 11:528-535.
40. Risitano A.M., Ricklin D., Huang Y., Reis E.S., Chen H., Ricci P., Lin Z., Pascariello C., Raia M., Sica M., Del Vecchio L., Pane F., Lupu F., Notaro R., Resuello R.R.G., DeAngelis R.A., Lambris J.D. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014, 123:2094-2101. 10.1182/blood-2013-11-536573.
41. Rondelli T., Risitano A.M., Peffault de Latour R., Sica M., Peruzzi B., Ricci P., Barcellini W., Iori A.P., Boschetti C., Valle V., Frémeaux-Bacchi V., De Angioletti M., Socie G., Luzzatto L., Notaro R. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica 2014, 99:262-266. 10.3324/haematol.2013.090001.
42. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 2007, 25:1256-1264. 10.1038/nbt1344.
43. Schmidt C.Q., Bai H., Lin Z., Risitano A.M., Barlow P.N., Ricklin D., Lambris J.D. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J. Immunol. 2013, 190:5712-5721. 10.4049/jimmunol.1203548.
44. Schmidt C.Q., Herbert A.P., Hocking H.G., Uhrín D., Barlow P.N. Translational mini-review series on complement factor H: structural and functional correlations for factor H: structure-function of factor H. Clin. Exp. Immunol. 2007, 151:14-24. 10.1111/j. 1365-2249.2007.03553. x.
45. Schmidt C.Q., Herbert A.P., Kavanagh D., Gandy C., Fenton C.J., Blaum B.S., Lyon M., Uhrín D., Barlow P.N. A new map of glycosaminoglycan and C3b binding sites on factor H. J. Immunol. 2008, 181:2610-2619.
46. Schmidt C.Q., Kennedy A.T., Tham W.-H. More than just immune evasion: hijacking complement by plasmodium falciparum. Mol. Immunol. 2015, 10.1016/j.molimm.2015.03.006.
47. Schmidt C.Q., Slingsby F.C., Richards A., Barlow P.N. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr. Purif. 2011, 76:254-263. 10.1016/j.pep.2010.12.002.
48. Sofat R., Mangione P.P., Gallimore J.R., Hakobyan S., Hughes T.R., Shah T., Goodship T., D'Aiuto F., Langenberg C., Wareham N., Morgan B.P., Pepys M.B., Hingorani A.D. Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. J. Immunol. Methods 2013, 390:63-73. 10.1016/j.jim.2013.01.009.
49. Sun X., Funk C.D., Deng C., Sahu A., Lambris J.D., Song W.C. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:628-633.
50. Telen M.J., Green A.M. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood 1989, 74:437-441.
51. Tham W.-H., Wilson D.W., Lopaticki S., Schmidt C.Q., Tetteh-Quarcoo P.B., Barlow P.N., Richard D., Corbin J.E., Beeson J.G., Cowman A.F. Complement receptor 1 is the host erythrocyte receptor for plasmodium falciparum PfRh4 invasion ligand. Proc. Natl. Acad. Sci. 2010, 107:17327-17332. 10.1073/pnas.1008151107.
52. van den Elsen J.M.H., Isenman D.E. A crystal structure of the complex between human complement receptor 2 and its ligand C3d. Science 2011, 332:608-611. 10.1126/science.1201954.
53. Verhave J.C., Wetzels J.F.M., van de Kar N.C.A.J. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 2014, 29(Suppl. 4):iv131-iv141. 10.1093/ndt/gfu235.
54. Wang C.-Y., Wang S.-W., Huang W.-C., Kim K.S., Chang N.-S., Wang Y.-H., Wu M.-H., Teng C.-H. Prc contributes to Escherichia coli evasion of classical complement-mediated serum killing. Infect. Immun. 2012, 80:3399-3409. 10.1128/iai.00321-12.
55. Wilson J.G., Murphy E.E., Wong W.W., Klickstein L.B., Weis J.H., Fearon D.T. Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J. Exp. Med. 1986, 164:50-59.
56. Xiang L., Rundles J.R., Hamilton D.R., Wilson J.G. Quantitative alleles of CR1: coding sequence analysis and comparison of haplotypes in two ethnic groups. J. Immunol. 1999, 163:4939-4945.
57. Yanagawa B., Spiller O.B., Choy J., Luo H., Cheung P., Zhang H.M., Goodfellow I.G., Evans D.J., Suarez A., Yang D., McManus B.M. Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab. Investig. J. Tech. Methods Pathol. 2003, 83:75-85.